Dr. Rahul Roy Chowdhury is a consultant in Gynaecology and Gynaecological Oncology at Manipal Hospitals, Kolkata, with 33 years of overall clinical experience, including 19 years as a specialist. He completed his MBBS from the University of Calcutta and underwent extensive medical training in the United Kingdom. He holds MRCOG and FRCOG qualifications from the Royal College of Obstetricians and Gynaecologists, London. His clinical work focuses on complex gynaecologic oncological surgeries and minimally invasive laparoscopic procedures.

Educational Qualifications

• MBBS – University of Calcutta
• MRCOG – Royal College of Obstetricians and Gynaecologists, London
• FRCOG – Royal College of Obstetricians and Gynaecologists, UK
• Certificate of Completion of Training (CCT) – Professional Medical Educational and Training Board, UK

Professional Experience

• Consultant – Gynaecological Oncology Specialist, Manipal Hospitals,  Kolkata
• 33 years of overall clinical experience
• 19 years as a specialist in Gynaecological Oncology
• Practised medicine and underwent advanced training in the United Kingdom
• Specialised training in Gynaecological Oncology at Oxford Cancer Centre, John Radcliffe Hospital

Awards & Achievements

• Local Mentor for In-Country IGCS Fellowship, India
• LMIC Representative for the 1st Endometrial Cancer Consensus Conference for Clinical Research (ECCC-CR), Seoul, Korea (November 2–3, 2023)
• Resource person for training consultants at Chittagong Medical College, Chittagong, Bangladesh

Professional Memberships

• Fellow of the Royal College of Obstetricians and Gynaecologists, UK (FRCOG)
• Member of the Royal College of Obstetricians and Gynaecologists, UK (MRCOG)
• Member of the Association of Gynaecologic Oncology
• Member of the Gynae Cancer InterGroup
• Founding Member – Kolkata Gynecological Oncology Trials and Translational Research Group

Certifications

• Certificate of Completion of Training (CCT), UK

Fellowships

• Fellowship – Royal College of Obstetricians and Gynaecologists, UK (FRCOG)

Publications

• Ghosh DD, Chowdhury RR, Dutta R, Mukhopadhyay I, Mukhopadhyay A, Roychoudhury S. In-silico analysis of TCGA data showing multiple POLE-like favourable subgroups overlapping with TP53 mutated endometrial cancer: Implications for clinical practice in low and middle-income countries. Gynecologic Oncology Reports, 2023.
• Mandal P, Bhattacharjee B, Sen S, Bhattacharya A, Saha SS, Chowdhury RR, Mondal NR, Chakrabarty B, Chatterjee T, Roy S, Sengupta S. Predominance of genomically defined A lineage of HPV16 over D lineage in Indian patients from eastern India with squamous cell carcinoma of the cervix in association with distinct oncogenic phenotypes. Translational Oncology, 2021.
• Kurtz JE, Gebski V, Sukhin V, Carey M, Kong I, Glasspool RM, Berek JS, de Paiva Batista M, Hall M, Kim JW, Yeoshoua E, Fujiwara N, Nam BH, Polleis S, Lee JY, Strojna A, Farrelly L, Schwameis R, Fossati R, Darlington AS, Lai CH, Wright AA, Rosenblat O, Harter P, Roxburgh P, Chowdhury RR, Chang TC, Paoletti X, Friedlander M. Incorporating patient centered benefits as endpoints in randomized trials of maintenance therapies in advanced ovarian cancer: A position paper from the GCIG symptom benefit committee. Gynecologic Oncology, 2021.
• Mukhopadhyay A, Ghosh T, Bhattacharjee D, Chakraborty D, Gupta, Roychowdhury I, Chatterjee P, Vemekar M, Chowdhury RR. Intermittent PARP Inhibitor Regimen In Ovarian Cancer (IPIROC): Origin and feasibility of implementing a proof-of-concept exploratory study. IGCS Abstracts, October 18, 2023.